Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
Become a Member | Sign in
Home>News>This Article

Metabolon Launches Fourth Generation DiscoveryHD4™ Metabolomics Platform

Published: Saturday, April 05, 2014
Last Updated: Saturday, April 05, 2014
Bookmark and Share
New technology advancements have potential to lead the way to new scientific breakthroughs, novel biomarkers and discoveries, and support diagnostic product pipeline.

Metabolon, Inc. has announced the launch of DiscoveryHD4™, the company’s fourth-generation metabolomics platform.

This new technology platform will empower the company's metabolomics TrueVision™, mVision™ and mView™ research and biomarker discovery offerings, as well as its diagnostic product development pipeline.

Further extending Metabolon's leadership position in metabolomics research and diagnostics, this platform enables a more expansive and precise global biochemical coverage of metabolite markers across the entire metabolome, thus increasing the ability to discover novel biomarkers and research questions.

Two key innovations power the DiscoveryHD4™ platform advancements. First, accurate mass instrumentation coupled to our new software technology provides a profound increase in sensitivity, and leads to the detection of more metabolites with greater precision.

Second adding a hydrophilic interaction chromatography (HILIC) method to the company’s standard platform technology provides a more complete picture for metabolites within central carbon, or “energy,” metabolism, among other advances.

The novel software tools that Metabolon has pioneered leverages these technical advancements. Together with Metabolon’s wealth of biochemistry expertise, these advancements are significant ingredients to Metabolon’s leadership and success in metabolomics.

“This new technology platform advances the evolution of our metabolomics capabilities and intellectual property,” said John Ryals, Ph.D, President and CEO of Metabolon. “These capabilities are a primary reason we are seeing more collaborations with large initiatives such as the one we recently announced with Craig Venter’s new genomics initiative, Human Longevity Inc. There is growing recognition of the value metabolomics offers to empower genomics and connect genetics to the phenotype, or the living system’s observable characteristics. Having a metabolomics technology platform with an industrialized capability and a capacity that can keep pace with the power of modern sequencing technologies is important to maintaining our position of industry leadership. The breadth of metabolome coverage that this new platform now provides enables more mechanistic insight into the basis of human health and disease.”

“Our scientists are ecstatic about the enhanced resolving power that the DiscoveryHD4™ will deliver our clients across academia and the biotechnology industry. We are already leveraging the enhanced resolving power of the new platform to fuel our diagnostic biomarker discovery pipeline,” commented Michael Milburn, Ph.D., Chief Scientific Officer of Metabolon.

Milburn continued, “Not only are we able to identify more metabolite markers than ever before, we have extended our capabilities to routinely measure additional classes such as steroids and energy metabolites. With these advancements, we can take a complex sample, such as blood, and rapidly identify and rigorously quality control up to 1,000 metabolites in a single biological sample, more than many have thought possible. Practically, this means our potential to discover more sensitive and specific biomarkers and understand what these signatures mean for the underlying biology is dramatically heightened.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Global Genomics Group and Metabolon to Collaborate
Metabolon will conduct biochemical profiling in single largest prospective pan-omic study.
Thursday, November 14, 2013
Biomarkers of Prostate Cancer Progression Identified with Biochemical Profiling Technology
Using Metabolon’s biochemical profiling, the researchers identified a series of metabolites that are key potential predictors of cancer aggressiveness.
Thursday, February 12, 2009
Metabolon Appoints Chief Scientific Officer
Dr. Michael Milburn has been appointed as Chief Scientific Officer.
Wednesday, November 09, 2005
Scientific News
NIH Supports New Studies to Find Alzheimer’s Biomarkers in Down Syndrome
Initiative will track dementia onset, progress in Down syndrome volunteers.
New Gene Map Reveals Cancer’s Achilles’ Heel
Team of researchers switches off almost 18,000 genes
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Ancient Viral Molecules Essential for Human Development
Genetic material from ancient viral infections is critical to human development, according to researchers at the Stanford University School of Medicine.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Personalized Drug Screening for Multiple Myeloma Patients
A personalized method for testing the effectiveness of drugs that treat multiple myeloma may predict quickly and more accurately the best treatments for individual patients with the bone marrow cancer.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
New Way to Force Stem Cells to Become Bone Cells
Potential therapies based on this discovery could help people heal bone injuries or set hardware, such as replacement knees and hips.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos